In breast cancer cell lines, we showed [25] that PTPN13 has a negative effect, via insulin receptor substrate 1 (IRS1) dephosphorylation, on the activation of PI3K, one of the driver pathways in ovarian cancer [2]. Here, PTPN13 is linked to ovarian cancer.